POST Online Media Lite Edition



 

Dendreon announces leadership transition

Staff writer |
Seattle, Wa., USA - June 11, 2014, Seattle, Wa., USA - Dendreon Corporation announces that John H. Johnson has informed the board of directors of his plans to step down as president and chief executive officer for personal reasons.




Mr. Johnson has resigned from the Board, effective June 3, 2014, and will serve as chief executive officer until August 15, 2014.

Mr. Johnson serves as chairman, president and chief executive officer of Dendreon. Mr. Johnson has served as a member of Dendreon's Board of Directors since August 2011. Prior to joining Dendreon, he was the chief executive officer and a member of the Board of Directors of Savient Pharmaceuticals, Inc., from January 2011 through January 2012.

Prior to that position, Mr. Johnson served as president of Eli Lilly & Company's Oncology Unit, following the company's 2008 acquisition of Imclone Systems, Inc., where he served as chief executive officer.

Prior to joining Imclone, he served as the Company Group Chairman of Biopharmaceuticals within Johnson & Johnson, where he was responsible for the Johnson & Johnson Biotechnology, Immunology and Oncology commercial businesses.

Prior to assuming that role, he held several executive positions at Johnson & Johnson, Parkstone Medical Information Systems, Inc., Ortho-McNeil Pharmaceutical Corp., as well as positions at Pfizer, Inc. He is the former Chairman of Tranzyme Pharma, Inc., and is currently a member of the Board of Directors for Cempra Pharmaceuticals, Inc., and Histogenics.

He also serves as a member of the Board of Directors for the Pharmaceutical Research and Manufacturers of America (PhRMA) and as a member of the Health Section Governing Board of Biotechnology Industry Organization (BIO).

The Board has elected Douglas G. Watson, Dendreon's lead independent director, as chairman of the Board.

Mr. Watson has served as one of Dendreon's independent directors since February 2000. He is chief executive officer of Pittencrieff Glen Associates, a consulting firm that he founded in 1999.

Prior to that, Mr. Watson's career spanned 33 years with Geigy/Ciba-Geigy/Novartis, during which time he held a variety of positions in the UK, Switzerland and the U.S. He was president of Ciba U.S. Pharmaceuticals Division from 1986-1996, when he was appointed president and chief executive officer of Ciba-Geigy U.S. Corporation.

LATEST 5 MOVES FROM Washington 


What to read next

Dendreon elects David C. Stump to board of directors
Dendreon: John H. Johnson assumes role of chairman
Dendreon announces change in board of directors